MARKET

SABSW

SABSW

SAB BIOTHERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1400
-0.0456
-24.57%
Closed 16:00 08/11 EDT
OPEN
0.1662
PREV CLOSE
0.1856
HIGH
0.1900
LOW
0.1118
VOLUME
61.29K
TURNOVER
7.85K
52 WEEK HIGH
3.320
52 WEEK LOW
0.1000
MARKET CAP
--
P/E (TTM)
-0.2510
1D
5D
1M
3M
1Y
5Y
BRIEF-Sab Biotherapeutics Says Cash And Cash Equivalents Were $16.6 Mln As Of June 30
BRIEF-Sab Biotherapeutics Says Cash And Cash Equivalents Were $16.6 Mln As Of June 30
Reuters · 1d ago
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results
Expects cash is sufficient to fund operations for the forward twelve monthsSIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that p...
GlobeNewswire · 1d ago
BRIEF-Sab Biotherapeutics Advancing Pipeline And Expands Into Treatment For C. Diff. As Dod Contract Winds Down
BRIEF-Sab Biotherapeutics Advancing Pipeline And Expands Into Treatment For C. Diff. As Dod Contract Winds Down
Reuters · 2d ago
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibod...
GlobeNewswire · 2d ago
SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first of its kind immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal an...
GlobeNewswire · 08/04 12:30
BRIEF-Sab Biotherapeutics Elects Scott Giberson To Board Of Directors
BRIEF-Sab Biotherapeutics Elects Scott Giberson To Board Of Directors
Reuters · 07/11 12:06
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibod...
GlobeNewswire · 07/11 12:00
SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour
SIOUX FALLS, S.D., July 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human ...
GlobeNewswire · 07/05 12:00
More
No Data
Learn about the latest financial forecast of SABSW. Analyze the recent business situations of SAB BIOTHERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-0.52-0.39-0.25-0.11
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About SABSW
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. The Company uses its immunotherapy platform, DiversitAb, to produce a new class of specifically targeted, fully human polyclonal antibodies without the need for human donors and applies to a range of serious unmet needs in human diseases. The Company's product candidates include SAB-185, which is a fully human polyclonal antibody therapeutic for the treatment of Coronavirus disease (COVID-19), and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. The Company's pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction and early discovery work in oncology.

Webull offers kinds of SAB Biotherapeutics Inc stock information, including NASDAQ:SABSW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABSW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SABSW stock methods without spending real money on the virtual paper trading platform.